Disease Domain | Count |
---|---|
Infectious Diseases | 2 |
Nervous System Diseases | 1 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Synthetic peptide | 2 |
Target- |
Mechanism Bacterial biofilms inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Bacterial biofilms inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Apr 2024 |
Sponsor / Collaborator |
Start Date20 Jan 2024 |
Sponsor / Collaborator |
Start Date09 Dec 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Pexiganan Acetate | Bacterial Infections More | Preclinical |
MSI-594 | Bacterial Infections More | Preclinical |
MSI-367 | Bacterial Infections More | Pending |
MSI-843 | Bacterial Infections More | Pending |